Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...
An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for babies found it to be almost 90% effective in reducing hospitalization ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
Largest childhood preventative health initiative in nearly 20 yearsBeyfortus rollout to ensure all babies are RSV protected this winterThe largest ...
The authors assessed the patient characteristics associated with RSV vaccination among older adults hospitalized during the ...
The Royal Australian College of GPs (RACGP) has thrown its support behind Victoria's infant RSV vaccine program. Respiratory syncytial virus, or RSV ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...
Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback